As the global population continues to age and the prevalence of chronic diseases continues to rise, the demand for advanced healthcare solutions remains steadfast. This ongoing need is poised to create a sustained and robust market for biotech products.
In such a scenario, investors could consider buying three fundamentally sound biotech stocks, Equillium, Inc. (EQ), Theratechnologies Inc. (THTX), and Exelixis, Inc. (EXEL), which are well-poised to capitalize on the industry’s consistent demand.
